UI Hospitals and Clinics

Clinical Trial Details

Short Title
LEE011 + letrozole in postmenopausal women w/ hormone receptor pos, HER2-neg, advanced breast cancer
Official Title

A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease


Participants in this study have been diagnosed with breast cancer. Studies have shown that blocking a certain pathway has the potential to control ER+ breast cancer progression. The purpose of this study is to test the efficacy of using LEE011 in combination with letrozole to prolong progression free survival in postmenopausal women with advanced breast cancer.
About 500 participants will take part in this study at multiple sites; approximately 16 participants will take part in this study at the University of Iowa.

Start Date
April 21, 2014
End Date
December 3, 2014
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Alexandra Thomas, MD
Contact Info

Michelle Arnold     319-356-2778

Breast ; Cancer ; letrozole ; Phase 3 ; Phase iii ; Thomas ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.